APRINOIA Therapeutics Inc. (APRI)

APRINOIA Therapeutics was planning to go public, but the IPO was withdrawn on Oct 28, 2024.

IPO Price Range

$10.00 - $12.00

Shares Offered

500,000

Deal Size

$5.50M

APRINOIA Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	9.13	0.39	0.55
Revenue Growth (YoY)	-	-28.36%	-
Gross Profit	9.13	0.39	0.55
Selling, General & Admin	-	7.04	4.79
Research & Development	-	21.62	19.66
Operating Expenses	-	28.66	24.45
Operating Income	-21.16	-28.26	-23.9
Interest Expense / Income	1.5	0.07	0.04
Other Expense / Income	-0.98	-0.12	-0.67
Pretax Income	-21.68	-28.21	-23.26
Income Tax	0.06	0.02	-
Net Income	-21.74	-28.23	-23.26
Free Cash Flow	-14.14	-19.25	-24.8
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-231.67%	-7173.60%	-4344.91%
Profit Margin	-238.04%	-7165.23%	-4229.27%
Free Cash Flow Margin	-154.81%	-4886.55%	-4509.09%
EBITDA	-19.63	-27.7	-22.91
EBITDA Margin	-214.98%	-7031.47%	-4164.91%
Depreciation & Amortization	0.54	0.44	0.32
EBIT	-20.18	-28.15	-23.23
EBIT Margin	-220.94%	-7143.91%	-4222.73%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).